{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:47:34Z","timestamp":1648615654299},"reference-count":44,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sao Paulo Med. J."],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:p>CONTEXT AND OBJECTIVE: The choice of an antihypertensive drug is based on several criteria and specific situations give rise to doubt and controversy. The aim here was to evaluate physicians\u2019 approaches towards treatment with antihypertensive agents in specific situations. DESIGN AND SETTING: Cross-sectional study, at Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo. METHODS: A questionnaire was applied during a nephrology meeting to evaluate individual approaches towards each hypothetical clinical situation. The questionnaire consisted of five multiple-choice questions (clinical cases) concerning controversial aspects of antihypertensive therapy. RESULTS: A total of 165 questionnaires were analyzed. Most participants were nephrologists (93.2%). There was a preference for angiotensin-converting enzyme (ACE) inhibitors in at least two of the cases. Only 57.2% of the physicians were correct in choosing beta-blockers as the first-line drugs for patients with ischemic coronary disease. Moreover, 66.2% chose ACE inhibitors as the first-line drugs for patients with chronic kidney disease and proteinuria. About 5% of the physicians did not follow the current recommendations for the use of ACE inhibitors in diabetic patients with microalbuminuria. The most controversial question concerned the first-line drug for advanced chronic kidney disease. Most physicians were correct in choosing calcium channel blockers and avoiding ACE inhibitors in renovascular hypertension in the case of a patient with a single functioning kidney. CONCLUSIONS: Most physicians adopted the correct approach, but some had an alternative strategy for the same situations that was not based on evidence.<\/jats:p>","DOI":"10.1590\/s1516-31802008000100007","type":"journal-article","created":{"date-parts":[[2008,4,16]],"date-time":"2008-04-16T22:59:17Z","timestamp":1208386757000},"page":"34-40","source":"Crossref","is-referenced-by-count":0,"title":["Divergences in antihypertensive therapy in special situations in nephrology"],"prefix":"10.1590","volume":"126","author":[{"given":"Marcelo Montebello","family":"Lemos","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra Coelho","family":"Pedrosa","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alze Pereira","family":"Tavares","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c2ngelo","family":"G\u00f3es","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9rgio Ant\u00f4nio","family":"Draibe","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Sesso","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"19","key":"ref1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian AV","year":"2003","journal-title":"JAMA."},{"issue":"5","key":"ref2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis."},{"key":"ref3","first-page":"7","article-title":"IV Diretrizes Brasileiras de Hipertens\u00e3o Arterial: IV Brazilian Guidelines on Hypertension","volume":"82","year":"2004","journal-title":"Arq Bras Cardiol."},{"issue":"7","key":"ref4","first-page":"2092","article-title":"ACC\/AHA\/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina)","volume":"33","author":"Gibbons RJ","year":"1999","journal-title":"J Am Coll Cardiol."},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","year":"1981","journal-title":"N Engl J Med."},{"issue":"6","key":"ref6","first-page":"I26","article-title":"The G\u00f6teborg metoprolol trial: Effects on mortality and morbidity in acute myocardial infarction","volume":"67","author":"Hjalmarson A","year":"1983","journal-title":"Circulation."},{"issue":"8885","key":"ref7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0140-6736(93)92930-R","article-title":"Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group","volume":"342","author":"Waagstein F","year":"1993","journal-title":"Lancet."},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson A","year":"2000","journal-title":"JAMA."},{"issue":"21","key":"ref9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer M","year":"1996","journal-title":"N Engl J Med."},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.167586","article-title":"ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society","volume":"112","author":"Hunt SA","year":"2005","journal-title":"Circulation."},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0735-1097(00)01111-6","article-title":"Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade","volume":"37","author":"van den Heuvel AF","year":"2001","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2003.07.027","article-title":"Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial","volume":"42","author":"Pepine CJ","year":"2003","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"95B","DOI":"10.1016\/0002-9149(87)90088-9","article-title":"Calcium antagonists for chronic stable angina pectoris","volume":"59","author":"Krikler DM","year":"1987","journal-title":"Am J Cardiol."},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","article-title":"ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)","volume":"110","author":"Antman EM","year":"2004","journal-title":"Circulation."},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/ki.1990.217","article-title":"Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?","volume":"38","author":"Remuzzi G","year":"1990","journal-title":"Kidney Int."},{"issue":"252","key":"ref16","first-page":"343","article-title":"Renal pathology and proteinuria determine progression in untreated mild\/moderate chronic renal failure","volume":"67","author":"Williams PS","year":"1988","journal-title":"Q J Med."},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson JC","year":"1995","journal-title":"Ann Intern Med."},{"key":"ref18","first-page":"S174","article-title":"Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease","volume":"45","author":"Apperloo AJ","year":"1994","journal-title":"Kidney Int Suppl."},{"issue":"9069","key":"ref19","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy: The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet."},{"issue":"15","key":"ref20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio G","year":"1996","journal-title":"N Engl J Med."},{"issue":"9352","key":"ref21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao N","year":"2003","journal-title":"Lancet."},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"Gross JL","year":"2005","journal-title":"Diabetes Care."},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0272-6386(03)00826-6","article-title":"Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)","volume":"42","author":"Eknoyan G","year":"2003","journal-title":"Am J Kidney Dis."},{"issue":"7448","key":"ref24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.38070.450891.FE","article-title":"Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study","volume":"328","author":"Hovind P","year":"2004","journal-title":"BMJ."},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF00403306","article-title":"Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria: The Microalbuminuria Captopril Study Group","volume":"39","year":"1996","journal-title":"Diabetologia."},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria: European Microalbuminuria Captopril Study Group","volume":"271","author":"Viberti G","year":"1994","journal-title":"JAMA."},{"issue":"9068","key":"ref27","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria: The EUCLID Study Group","volume":"349","year":"1997","journal-title":"Lancet."},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0272-6386(05)80003-4","article-title":"Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria","volume":"37","author":"Jerums G","year":"2001","journal-title":"Am J Kidney Dis."},{"issue":"23","key":"ref29","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa021835","article-title":"Regression of microalbuminuria in type 1 diabetes","volume":"348","author":"Perkins BA","year":"2003","journal-title":"N Engl J Med."},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen P","year":"2003","journal-title":"Kidney Int."},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy","volume":"14","author":"Jacobsen P","year":"2003","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner BM","year":"2001","journal-title":"N Engl J Med."},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1097\/01.ASN.0000146423.71226.0C","article-title":"Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results","volume":"15","author":"Remuzzi G","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"23","key":"ref34","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA."},{"issue":"16","key":"ref35","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra020676","article-title":"Renal dysfunction complicating the treatment of hypertension","volume":"347","author":"Palmer BF","year":"2002","journal-title":"N Engl J Med."},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou FF","year":"2006","journal-title":"N Engl J Med."},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe058295","article-title":"Optimizing ACE-inhibitor therapy for chronic kidney disease","volume":"354","author":"Hebert LA","year":"2006","journal-title":"N Engl J Med."},{"issue":"9","key":"ref38","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1161\/CIRCULATIONAHA.104.492348","article-title":"Renovascular hypertension and ischemic nephropathy","volume":"112","author":"Garovic VD","year":"2005","journal-title":"Circulation."},{"issue":"6","key":"ref39","first-page":"339","article-title":"Survival of patients with renovascular disease and ACE inhibition","volume":"52","author":"Losito A","year":"1999","journal-title":"Clin Nephrol."},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM198302173080706","article-title":"Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney","volume":"308","author":"Hricik DE","year":"1983","journal-title":"N Engl J Med."},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/ki.1994.290","article-title":"Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats","volume":"46","author":"V\u00e9niant M","year":"1994","journal-title":"Kidney Int."},{"issue":"16","key":"ref42","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Hearth Association: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association","volume":"104","author":"Schoolwerth AC","year":"2001","journal-title":"Circulation."},{"issue":"8370","key":"ref43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(84)92149-4","article-title":"Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure","volume":"1","author":"Jackson B","year":"1984","journal-title":"Lancet."},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/00004872-200111000-00026","article-title":"European Society of Hypertension: How to handle renovascular hypertension","volume":"19","author":"Alcazar JM","year":"2001","journal-title":"J Hypertens."}],"container-title":["Sao Paulo Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/spmj\/v126n1\/a07v1261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T20:27:34Z","timestamp":1495744054000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-31802008000100007&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S1516-31802008000100007"],"URL":"https:\/\/doi.org\/10.1590\/s1516-31802008000100007","relation":{},"ISSN":["1516-3180"],"issn-type":[{"value":"1516-3180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}